In 2018, three CGRP blockers were approved by the FDA for the prevention of migraine: erenumab; fremanezumab; and galcanezumab. :The calcitonin gene-related peptide (CGRP) is a therapeutic target in migraine because of its hypothesized role in mediating trigeminovascular pain transmission and the vasodilatory component of<unk>  (see "Pathophysiology, clinical manifestations, and diagnosis of migraine in adults", section on 'Role of calcitonin gene-related peptide'). In 2018, the US Food and Drug Administration (FDA) approved the CGRP antagonists erenumab 36, fremanezumab 37, and galcanezumab 38 for migraine prevention. :Smith, "Preventive treatment of migraine in adults" UpToDate 2019 Additional CGRP blockers are progressing through clinical trials. Anticipating later botox therapy for migraine, early work by Jancsó et al. found some success in treatment using denervation or pretreatment with capsaicin to prevent uncomfortable symptoms of<unk> . A 2010 study of the treatment of migraine with CGRP blockers had shown promise for CGRP blockers. In early trials, the first oral nonpeptide CGRP antagonist, MK-0974 (Telcagepant), was shown effective in the treatment of migraine attacks, but elevated liver enzymes in two participants were found. Other therapies and other links in the<unk>  inflammatory pathway for interruption of disease are under study, including migraine therapies. Noting that botulinum toxin has been shown to have an effect on inhibiting<unk> , and evidence suggesting the role of<unk>  in the pathogenesis of psoriasis, the University of Minnesota has a pilot clinical trial underway to follow up on the observation that patients treated with botulinum toxin for dystonia had dramatic improvement in psoriasis. Astelin (Azelastine) "is indicated for symptomatic treatment of vasomotor rhinitis including rhinorrhea, nasal congestion, and post nasal drip in adults and children 12 years of age and older." Statins appear to "decrease expression of the proinflammatory neuropeptides calcitonin gene-related peptide and substance P in sensory neurons," and so might be of use in treating diseases presenting with predominant<unk> .
Neurogenic inflammation
Neuroinflammation
Central nervous system fatigue
Visual pathway lesions
Neurolathyrism
Hypothalamic disease
Ischemic compression
Central nervous system viral disease